2012AAN NSAID和其他补充剂防治成人发作性偏头痛循证指南

2012-04-27 国神经病学会和头痛学会 Neurology

NSAIDs+and+other+complementary+treatments+for+episodic+migraine+prevention+in+adults.pdf 美国神经病学会和美国头痛学会在第64届美国神经病学会年会上发布了该指南。 指南制订专家组分析了1999年6月至2009年5月发表的有关研究。 结果显示,专家组回顾了284项研究摘要,最终共获得49项Ⅰ或Ⅱ类研究,其中

NSAIDs+and+other+complementary+treatments+for+episodic+migraine+prevention+in+adults.pdf

美国神经病学会和美国头痛学会在第64届美国神经病学会年会上发布了该指南。

指南制订专家组分析了1999年6月至2009年5月发表的有关研究。

结果显示,专家组回顾了284项研究摘要,最终共获得49项Ⅰ或Ⅱ类研究,其中15项被认为包含非传统治疗、NSAID和其他补充治疗。

双丙戊酸钠(divalproex sodium)、丙戊酸钠(sodium valproate)、托吡酯(topiramate)、美托洛尔(metoprolol)、普萘洛尔(propranolol)和噻吗洛尔(timolol)是有效的偏头痛预防药物,应当给予偏头痛患者这些药物,以降低偏头痛发作频率和严重性(A级推荐)。

夫罗曲坦(frovatriptan)可有效预防月经性偏头痛(A级推荐)。

拉莫三嗪(lamotrigine)对偏头痛无预防作用(A级推荐)。

蜂斗菜(款冬)可有效预防偏头痛,应推荐患者使用,以降低偏头痛发作的频率和严重性(A级推荐)。

非诺洛芬、布洛芬、酮洛芬、萘普生、萘普生钠、MIG-99(野甘菊)、镁、核黄素和皮下注射组织胺很可能对偏头痛有预防作用(B级推荐)。

赛庚啶、辅酶Q10、雌激素、甲芬那酸和氟比洛芬可能有效(C级推荐)。

阿司匹林、吲哚美辛、ω-3脂肪酸或高压氧可否预防偏头痛尚存争议。

孟鲁司特很可能对偏头痛无预防作用(B级推荐)。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793562, encodeId=26441e935623b, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun Nov 11 10:46:00 CST 2012, time=2012-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033792, encodeId=d0e42033e921c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 10 19:46:00 CST 2012, time=2012-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413616, encodeId=2ed7141361630, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446400, encodeId=369c14464007c, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449640, encodeId=4176144964003, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=)]
    2012-11-11 d830372
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793562, encodeId=26441e935623b, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun Nov 11 10:46:00 CST 2012, time=2012-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033792, encodeId=d0e42033e921c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 10 19:46:00 CST 2012, time=2012-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413616, encodeId=2ed7141361630, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446400, encodeId=369c14464007c, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449640, encodeId=4176144964003, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=)]
    2012-05-10 wjywjy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793562, encodeId=26441e935623b, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun Nov 11 10:46:00 CST 2012, time=2012-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033792, encodeId=d0e42033e921c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 10 19:46:00 CST 2012, time=2012-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413616, encodeId=2ed7141361630, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446400, encodeId=369c14464007c, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449640, encodeId=4176144964003, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=)]
    2012-04-29 amyloid
  4. [GetPortalCommentsPageByObjectIdResponse(id=1793562, encodeId=26441e935623b, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun Nov 11 10:46:00 CST 2012, time=2012-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033792, encodeId=d0e42033e921c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 10 19:46:00 CST 2012, time=2012-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413616, encodeId=2ed7141361630, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446400, encodeId=369c14464007c, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449640, encodeId=4176144964003, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=)]
    2012-04-29 bluefate123
  5. [GetPortalCommentsPageByObjectIdResponse(id=1793562, encodeId=26441e935623b, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun Nov 11 10:46:00 CST 2012, time=2012-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033792, encodeId=d0e42033e921c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 10 19:46:00 CST 2012, time=2012-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413616, encodeId=2ed7141361630, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446400, encodeId=369c14464007c, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449640, encodeId=4176144964003, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sun Apr 29 04:46:00 CST 2012, time=2012-04-29, status=1, ipAttribution=)]
    2012-04-29 xjy04

相关资讯

EASL/EORTC肝癌诊疗指南

  日前,欧洲肝脏研究学会(EASL)与欧洲癌症治疗研究组织(EORTC)联合发布了肝癌诊疗指南。       原文链接:http://www.easl.eu/_clinical-practice-guideline        

ADA/EASD糖尿病高血糖管理声明

  2型糖尿病的血糖管理已日趋复杂并伴随争议,随着可用药物的不断增多,有关药物潜在不良反应的担忧及强化血糖控制对于大血管并发症益处的不确定性不断增加。很多医生在为患者制定最佳策略时感到困惑。   为此,美国糖尿病学会(ADA)和欧洲糖尿病研究学会(EASD)召集了一个联合工作组,检验了证据并提出了非妊娠成人2型糖尿病患者降糖治疗的建议。ADA和EASD及其他学会和组织已经发布过几个相关的指南文件

2012中国“骨髓增生异常综合征诊疗共识”发布(附下载)

       骨髓增生异常综合征( MDS)是起源于造血干细胞的一组异质性髓系克隆性疾病,特点是髓系细胞发育异常,表现为无效造血、难治性血细胞减少、造血功能衰竭,高风险向急性髓系白血病(AML)转化。为规范临床诊治,中华医学会血液分会组织相关专家,讨论完成2012年《骨髓增生异常综合征诊断与治疗专家共识》,该共识发表在最新一期的《中华血液学杂志》上。 &n

ADA/EASD 2012年糖尿病指南解读和下载

  美国糖尿病学会(ADA,American Diabetes Association)和欧洲糖尿病研究协会(EASD,European Association for the Study of Diabetes)发表有关2型糖尿病治疗的最新立场声明,强调以患者为中心的治疗。      新指南的主要建议:   ? 必须根据患者具体特点制定个体化的血糖目标和降血糖治疗方

新指南勾画糖尿病管理地图:T2DM治疗步入患者为中心模式

  ADA/EASD发布立场声明,强调T2DM治疗目标和策略应个体化   美国糖尿病学会(ADA)与欧洲糖尿病研究学会(EASD)联合发布关于2型糖尿病(T2DM)高血糖管理的立场声明,强调以患者为中心的个体化治疗,并提出降糖策略推荐意见(图1)。声明4月19日在线发表于《糖尿病护理》(Diabetes Care)。(查看指南)   T2DM血糖管理日趋复杂,其原因包括数量和种类增多的药物

国家癌症中心将牵头制定癌症规范化治疗指南

       国家癌症中心年内有望在中国医学科学院肿瘤医院挂牌成立,其职能为建立健全国家三级癌症防治体系,发挥全国癌症登记、预防、规范化治疗以及药品研发等作用。   据了解,国家癌症中心隶属卫生部,中心总部设在中国医学科学院肿瘤医院。在昨天举行的搜狐健康媒体体验营上,院长赫捷介绍,癌症中心将整合全国肿瘤防控资源和癌症治疗方面的专家人才,组建高水平的专家指导委